A phase II study of metronomic oral topotecan for recurrent childhood brain tumors

Pediatric Blood and Cancer

Volumn 56, Issue 1, 2011, Pages 39-44

  Minturn, Jane E ^a   Janss, Anna J ^b   Fisher, Paul G ^c   Allen, Jeffrey C ^d   Patti, Ratnakar ^a   Phillips, Peter C ^a   Belasco, Jean B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b EMORY UNIVERSITY   (United States)

^c STANFORD UNIVERSITY   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Brain tumor; Medulloblastoma; Metronomic chemotherapy; Topotecan

Indexed keywords

TOPOTECAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BRAIN STEM GLIOMA; BRAIN TUMOR; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EPENDYMOMA; FEBRILE NEUTROPENIA; FEMALE; GLIOMA; HUMAN; HYPERURICEMIA; INFECTION; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUROECTODERM TUMOR; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR RECURRENCE;

BRAIN NEOPLASMS; BRAIN STEM NEOPLASMS; CHILD; DISEASE-FREE SURVIVAL; EPENDYMOMA; FEMALE; GLIOMA; HUMANS; MALE; NEUROECTODERMAL TUMORS, PRIMITIVE; TOPOISOMERASE I INHIBITORS; TOPOTECAN; TREATMENT OUTCOME;

EID: 78649651498     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22690     Document Type: Article

References (40)

1. Zwelling LA. DNA topoisomerase II as a target of antineoplastic drug therapy. Cancer Metastasis Rev 1985; 4: 263-276.
2. Yang Z, Carey JF, Champoux JJ. Mutational analysis of the preferential binding of human topoisomerase I to supercoiled DNA. FEBS J 2009; 276: 5906-5919.
3. De Cesare M, Zunino F, Pace S, et al. Efficacy and toxicity profile of oral topotecan in a panel of human tumour xenografts. Eur J Cancer 2000; 36: 1558-1564.
4. Houghton PJ, Cheshire PJ, Hallman JD, II, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995; 36: 393-403.
5. Motl S, Zhuang Y, Waters CM, et al. Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet 2006; 45: 871-903.
6. Blaney SM, Phillips PC, Packer RJ, et al. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 1996; 78: 527-531.
7. Rowinsky EK, Grochow LB, Hendricks CB, et al. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 1992; 10: 647-656.
8. Rose PG, Smrekar M, Haba P, et al. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer. Am J Clin Oncol 2008; 31: 476-480.
9. Puls LE, Phillips B, Schammel C, et al. A phase I-II trial of weekly topotecan in the treatment of recurrent cervical carcinoma. Med Oncol 2010; 27: 368-372.
10. Hochster H, Liebes L, Speyer J, et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J Clin Oncol 1994; 12: 553-559.
11. Zamboni WC, Bowman LC, Tan M, et al. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacol 1999; 43: 454-460.
12. Frangoul H, Ames MM, Mosher RB, et al. Phase I study of topotecan administered as a 21-day continuous infusion in children with recurrent solid tumors: A report from the Children's Cancer Group. Clin Cancer Res 1999; 5: 3956-3962.
13. Kadota RP, Stewart CF, Horn M, et al. Topotecan for the treatment of recurrent or progressive central nervous system tumors-A pediatric oncology group phase II study. J Neurooncol 1999; 43: 43-47.
14. Stewart CF, Iacono LC, Chintagumpala M, et al. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol 2004; 22: 3357-3365.
15. Rodriguez-Galindo C, Radomski K, Stewart CF, et al. Clinical use of topoisomerase I inhibitors in anticancer treatment. Med Pediatr Oncol 2000; 35: 385-402.
16. Houghton PJ, Cheshire PJ, Myers L, et al. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 1992; 31: 229-239.
17. Gerrits CJ, Schellens JH, Burris H, et al. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res 1999; 5: 69-75.
18. Burris HA, III, The evolving role of oral topotecan. Semin Hematol 1999; 36: 26-32.
19. Santana VM, Zamboni WC, Kirstein MN, et al. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res 2003; 9: 633-640.
20. Santana VM, Furman WL, Billups CA, et al. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol 2005; 23: 4039-4047.
21. Moghrabi A, Tien R, Fuchs H, et al. False positive images in the follow-up of patients with brain tumors. Med Pediatr Oncol 1997; 28: 127-131.
22. Giangaspero F, Perilongo G, Fondelli MP, et al. Medulloblastoma with extensive nodularity: A variant with favorable prognosis. J Neurosurg 1999; 91: 971-977.
23. Suresh TN, Santosh V, Yasha TC, et al. Medulloblastoma with extensive nodularity: A variant occurring in the very young-clinicopathological and immunohistochemical study of four cases. Childs Nerv Syst 2004; 20: 55-60.
24. de Chadarevian JP, Montes JL, O'Gorman AM, et al. Maturation of cerebellar neuroblastoma into ganglioneuroma with melanosis. A histologic, immunocytochemical, and ultrastructural study. Cancer 1987; 59: 69-76.
25. Pearl GS, Takei Y. Cerebellar "neuroblastoma": Nosology as it relates to medulloblastoma. Cancer 1981; 47: 772-779.
26. Shin WY, Laufer H, Lee YC, et al. Fine structure of a cerebellar neuroblastoma. Acta Neuropathol 1978; 42: 11-13.
27. Geyer JR, Schofield D, Berger M, et al. Differentiation of a primitive neuroectodermal tumor into a benign ganglioglioma. J Neurooncol 1992; 14: 237-241.
28. Hellbusch LC, Robinson MN, McComb RD, et al. Medulloblastoma with extensive nodularity: A report of two cases. Pediatr Neurosurg 2008; 44: 430-432.
29. Warzok R, Jaenisch W, Lang G. Morphology and biology of cerebellar neuroblastomas. J Neurooncol 1983; 1: 373-379.
30. Yagishita S, Itoh Y, Chiba Y, et al. Morphological investigations on cerebellar "neuroblastoma" group. Acta Neuropathol 1982; 56: 22-28.
31. Modha A, Vassilyadi M, George A, et al. Medulloblastoma in children-The Ottawa experience. Childs Nerv Syst 2000; 16: 341-350.
32. Roldan G, Brasher P, Vecil G, et al. Population-based study of medulloblastoma: Outcomes in Alberta from 1975 to 1996. Can J Neurol Sci 2008; 35: 210-215.
33. Dunkel IJ, Boyett JM, Yates A, et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group. J Clin Oncol 1998; 16: 222-228.
34. Perez-Martinez A, Lassaletta A, Gonzalez-Vicent M, et al. High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. J Neurooncol 2005; 71: 33-38.
35. Butturini AM, Jacob M, Aguajo J, et al. High-dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors: The impact of prior radiotherapy on outcome. Cancer 2009; 115: 2956-2963.
36. Bowers DC, Aquino VM, Leavey PJ, et al., Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors. Pediatr Blood Cancer 2004; 42: 93-98.
37. Daw NC, Santana VM, Iacono LC, et al. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. J Clin Oncol 2004; 22: 829-837.
38. Choi LM, Rood B, Kamani N, et al. Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors. Pediatr Blood Cancer 2008; 50: 970-975.
39. Needle MN, Molloy PT, Geyer JR, et al. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol 1997; 29: 28-32.
40. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 2006; 7: 813-820.